Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Reasner, C. A
Right arrow Articles by Göke, B.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Overcoming the barriers to effective glycaemic control for type 2 diabetes

Charles A Reasner

Texas Diabetes Institute and University of Texas Health Sciences Center, San Antonio, Texas, USA, creasner{at}university-health-sys.com

Burkhard Göke

Department of Internal Medicine , Ludwig-Maximilians University of Munich, Germany

References

  • European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • American Diabetes Association: clinical practice recommendations. Diabetes Care 1999;22(suppl 1):S1-114.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management - 2002 Update. Endocrine Practice 2002;8(suppl 1):40-82.[Medline] [Order article via Infotrieve]
  • New JP, Hollis S., Campbell F. et al. Measuring clinical performance and outcomes from diabetes information systems: an observational study. Diabetologia 2000;43:836-43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Liebl A., Neiss A., Spannheimer A., Reitberger U., Wagner T., Gortz A. Costs of type 2 diabetes in Germany. Results of the CODE-2 study. Dtsch Med Wochenschr 2001;126:585-9.[CrossRef][Medline] [Order article via Infotrieve]
  • Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999;22:403-08.[Abstract]
  • Banerji MA, Buckley MC, Chaiken RL, Gordon D., Lebovitz HE, Kral JG Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 1995;19:846-50.[Web of Science][Medline] [Order article via Infotrieve]
  • Banerji MA, Faridi N., Atluri R., Chaiken RL, Lebovitz HE Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84:137-44.[Abstract/Free Full Text]
  • Mokdad AS, Ford EH, Bowman BA et al. Diabetes trends in the US: 1990-1998. Diabetes Care 2000;23:1278-83.[Abstract/Free Full Text]
  • Day C. The rising tide of type 2 diabetes. Br J Diabetes Vasc Dis 2001;1:37-43.[Abstract/Free Full Text]
  • Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987;30:123-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gray A., Raikou M., McGuire A. et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 2000; 320:1373-8.[Abstract/Free Full Text]
  • Caro JJ, Ward AJ, O'Brien JA Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care 2002;25:476-81.[Abstract/Free Full Text]
  • Jönsson B. The economic impact of diabetes. Diabetes Care 1998;21 (suppl 3):C7-10.[Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stratton MI, Adler AI, Neil AW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.[Abstract/Free Full Text]
  • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • DeFronzo RA, Bonnadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318-68.[Abstract]
  • DeFronzo RA Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997;50:191-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995;44:1249-58.[Abstract]
  • Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.[Abstract/Free Full Text]
  • Bailey CJ Diabetes control: Treating a moving target. Internal Med 1996; 17:90-101.
  • Turner RC, Cull CA, Frighi V., Holman RR Glycaemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281:2005-12.[Abstract/Free Full Text]
  • Krentz AJ, Ferner RE, Bailey CJ Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994;11:223-41.[Web of Science][Medline] [Order article via Infotrieve]
  • Howlett HC, Bailey CJ A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20:489-503.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Haupt E., Knick B., Koschinsky T. et al. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab 1991;27:224-31.
  • Hermann LS, Schersten B., Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med 1994;11:953-60.[Web of Science][Medline] [Order article via Infotrieve]
  • Gribble FM, Manley SE, Levy JC Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care 2001;24:1221-25.[Abstract/Free Full Text]
  • Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 1996;19:849-56.[Abstract]
  • Garber AJ, Larsen J., Schneider SH, Piper BA, Henry D. Simultaneous glyburide/metformin monotherapy is superior to component monotherapy as initial pharmacological treatment for type 2 diabetes. Diab Obes Metab 2002;4:201-08.[CrossRef]
  • Moses R., Carter J., Slobodniuk R. et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119-24.[Abstract/Free Full Text]
  • DeFronzo RA, Goodman AM Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995;333:541-9.[Abstract/Free Full Text]
  • Charpentier G., Fleury F., Kabir M. et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001;16:828-34.
  • Marre M., Howlett H., Lehert P., Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance®) in type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002;19:673-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Blonde L., Rosenstock J., Mooradian AD, Piper BA, Henry D. Glyburide/ metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulfonylurea therapy. Diabetes Obes Metab (in press).
  • Veehof L., Stewart R., Haaijer-Ruskamp F., Jong BM The development of polypharmacy. A longitudinal study. Fam Pract 2000;17:261-7.[Abstract/Free Full Text]
  • Paes AHP, Bakker A., Soe-Agnie S-J. Impact of dosage frequency on patient compliance. Diabetes Care 1997;20:1512-17.[Abstract]
  • Brown JB, Nichols GA, Glauber HS, Bakst A. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin Ther 1999;21:1045-57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Morris AD, Brennan GM, Macdonald TM, Donnan PT. Population-Based Adherence to Prescribed Medication in Type 2 Diabetes: A Cause for Concern. Diabetes 2000;49(suppl 1):A76.
  • Donnan PT, MacDonald TM, Morris AD Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med 2002;19:279-84.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study (UKPDS) Group. Quality of life in type 2 diabetic patients is affected by complications but not by policies to improve blood glucose or blood pressure control. Diabetes Care 1999; 22:1125-36.[Abstract/Free Full Text]
  • Guidelines Subcommittee. 1999 World Health Organisation - International Society of Hypertension. Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-83.[Web of Science][Medline] [Order article via Infotrieve]
  • Joint National Committee. Sixth National Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-46.[Abstract/Free Full Text]
  • Winocour PH Effective diabetes care: a need for realistic targets. BMJ 2002;324:1577-80.[Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 4, 290-295 (2002)
DOI: 10.1177/14746514020020041001
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Reasner, C. A
Right arrow Articles by Göke, B.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?